Menu
Recruiting NCT06809231

Effectiveness and Safety of Knee Cartilage Lesion Treatment Using CartiONE: 1-to-13 Year Follow-up.

Observational Knee Cartilage Lesion

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Knee Cartilage Lesion. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium, Poland, United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effectiveness and Safety of Knee Cartilage Lesion Treatment Using CartiONE: 1-to-13 Year Follow-up

Overview

CartiONE is a technique used in autologous articular-chondrocyte-based treatments for symptomatic focal articular-cartilage lesions of the knee. The CartiONE technique was evaluated in combination with an osteochondrally placed, biodegradable, biocompatible, load-bearing copolymer (PolyActive) scaffold in the INSTRUCT trial (NCT01041885). To evaluate the clinical effectiveness of the CartiONE technique and confirm its safety, in this study retrospective baseline data and follow-up data, documented as per the standard of care at the participating hospitals, will be collected for patients who were treated with CartiONE. The potential number of patients in this study is 122 and involves patients treated with CartiONE from 2010 to 2023 with a minimum follow-up period of six months, spread across five countries: Belgium, England, Greece, Poland, and Austria.

Detailed description

Inclusion and exclusion criteria Inclusion criteria Patients treated with CartiONE for knee cartilage lesion more than 6 months prior to inclusion in this study.

The study site holds a patient record of all relevant medical history data, including operation reports of any prior knee surgeries, the index knee surgery report, and posttreatment observations and re-intervention reports, if applicable.

Exclusion criterion Patients cannot be included if any condition exists that is judged by the treating surgeon as making the patient not suited for participation.

Statistics This is a retrospective, open label, non-randomized, single arm trial. Since different questionnaires for effectiveness and for quality of life (e.g., KOOS, EQ-5D,…) may have been used, the total score of the questionnaires ranging from the minimum total score (i.e. 0 or 1) to the maximum total score will be transformed into the range from 0 respective 1 to 100. Now they can be combined across patients and effectiveness questionnaires or across patients and quality of life questionnaires. Details will be provided in the Statistical Analysis Plan.

There are two co-primary endpoints:

Primary endpoint safety:

Adverse events with particular focus on Treatment failure rate and on other AESIs

Primary endpoint effectiveness:

MOCART sub-score 1 "Volume fill of cartilage defect"

Efficacy/Effectiveness:

Key secondary endpoints:

Non-inferiority in MOCART/MOCART 2.0 total scores when measured at two different visits, i.e., at the reference visit and later.

Non-inferiority in mean "Radiologist's overall knee status assessment" when measured on a scale from 0 (extremely bad) to 100 (extremely good) at two different visits, i.e., at the reference visit and later.

Other secondary endpoints:

Improvement in other effectiveness questionnaire total scores Improvement in quality-of-life total scores Improvement in other questionnaires when applicable

Exploratory endpoint:

"Radiologist's overall knee status assessment" on a scale from 0 (extremely bad) to 100 (extremely good) of the two readers.

Primary outcome measures

  • Adverse events with particular focus on Treatment failure rate and on other AESIs [Time frame: periprocedurally, through to study completion up to 2 years]
  • MOCART sub-score 1 "Volume fill of cartilage defect" [Time frame: baseline, month 3, month 6, year 1, year 2]

Eligibility criteria

Inclusion criteria

  • Patients treated with CartiONE for knee cartilage lesion more than 6months prior to inclusion in this study.
  • The study site holds a patient record of all relevant medical history data, including operation reports of any prior knee surgeries, the index-knee surgery report, and posttreatment observations and re-intervention reports, if applicable.

Exclusion criteria

  • Patients cannot be included if any condition exists that is judged by the treating surgeon as making the patient not suited for participation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Belgium · 2 centers
  • UZ Ghent — Ghent
  • AZ Monica — Antwerp
United Kingdom · 2 centers
  • University Hospitals Coventry & Warwickshire NHS Trust — Coventry
  • Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust — Oswestry
Poland · 1 center
  • MIRAI — Warsaw

Identifiers

NCT: NCT06809231 · CRS001-2023 · IRAS ID 345492

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗